Status:
RECRUITING
Exploring the Frontiers of Neoadjuvant Therapy for Lung Cancer: a Prospective Observational Real-world Study
Lead Sponsor:
Shanghai Pulmonary Hospital, Shanghai, China
Conditions:
Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Lung cancer is a malignant tumor with the highest incidence and mortality rate of cancer patients worldwide. Traditional treatments for lung cancer include surgery, radiotherapy and chemotherapy, etc....
Detailed Description
Lung cancer is a malignant tumor with the highest incidence and mortality rate of cancer patients worldwide. Traditional treatments for lung cancer include surgery, radiotherapy and chemotherapy, etc....
Eligibility Criteria
Inclusion
- Age greater than or equal to 18 years;
- Pathohistologically confirmed diagnosis of non-small cell lung cancer or small cell lung cancer;
- Received neoadjuvant therapy after diagnosis;
- Written informed consent.
Exclusion
- Patients enrolled in other clinical trials;
- Patients refused enrollment in this study;
- Patients refused follow-up.
Key Trial Info
Start Date :
December 16 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 30 2033
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT06216782
Start Date
December 16 2023
End Date
December 30 2033
Last Update
January 22 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China, 200433